@ArmandDoma if Chan can combine the Asian vote with the open great highway vote and progressive vote, she might actually win. This may be partly about great highway, but she strongly carried the chinese vote.
@RuxandraTeslo If you are referring specifically to earlier assets, you might be right but mm has been one of the most successful areas for new products from the US and the unmet need has been greatly reduced and will be moreso inn next couple of years
I might disagree with this one. Several drugs looking better than car-t that originated here. . The bulk of novel Phase 3 MM assets are US-sponsored (or US-HQ’d): J&J’s teclistamab and talquetamab line extensions, Pfizer’s elranatamab (MagnetisMM), BMS’s ide-cel (KarMMa), the CELMoDs iberdomide and mezigdomide (BMS), Regeneron’s linvoseltamab, AbbVie/Genentech’s venetoclax in t(11;14) (CANOVA), and Kite/Gilead + Arcellx’s anito-cel — Kite announced the iMMagine-3 Phase 3 comparing anitocabtagene autoleucel